Clinical Trial Update: Dose-escalation Study of Safety of PBCAR19B in Participants With CD19-expressing Malignancies [Phase 1]

View source ↗

Summary

Phase 1 dose-escalation study update evaluating the safety of PBCAR19B in participants with CD19-expressing hematologic malignancies.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Malignancy

Drugs mentioned

• PBCAR19B

Snippet

Sponsor: Precision BioSciences, Inc. | Conditions: CD19 Expressing Malignancies, Hematologic Malignancy | Phase 1 | Status: COMPLETED